Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs single-agent chemotherapy in first-line advanced NSCLC not eligible for platinum doublet
CTR20171629Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jan 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20171629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171629.